Abstract 3969
Background
Overall colorectal cancer (CRC) incidence and mortality are declining due to cancer screening in older patients population, however, the incidence of CRC is increasing in younger adults (<50 years) among several countries, mostly in the United States and Europe. This study aimed to evaluateclinicopathological characteristics of adolescent and young adult (AYA) onset sporadic CRC and outcome in Thai patients.
Methods
Medical record of patients who were diagnosed adenocarcinoma of colorectal cancer at Siriraj Hospital between 2007 and 2018 were retrospectively reviewed. The patients were classified into 2 groups: AYA-onset CRC (age 15-39 years) and adult-onset CRC (age >50 years). Associations between sporadic microsatellite stable (MSS) AYA- /adult-onset CRC and clinicaopathological features and outcome were evaluated.
Results
A total 202 patients were diagnosed with AYA-onset CRC with no known history of familial CRC syndromes, 116 had data on mismatch repair status; 94 confirmed MSS CRC. AYA-onset CRC patients were commonly found with left-sided rather than right-sided tumors (77.7% vs 21.8%) and late stage of disease (72.7% in stage III-IV vs 24.7% in stage I-II). Compared with adult-onset CRC (195 patients), AYA-onset MSS CRC had more patients with female gender (p = 0.042), signet ring cell/mucinous histology (P = 0.039), and perineuralinvasion (P = 0.004). On univariate analysis, male gender and mucinous/signet ring cell histology had significantly worse OS (P = 0.003 and P = 0.016, respectively) and remained significant in multivariate analysis. There was no differences in terms of DFS or OS in both age groups.
Conclusions
Sporadic MSS AYA-onset CRC in Thai patients was associated with female gender and aggressive pathological characteristics. However, there was no difference in survival outcome between AYA-onset and adult-onset groups.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Siriraj Research Fund.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3353 - Results of the 3rd interim analysis of C-Patrol: A non-interventional study on olaparib in German routine clinical practice
Presenter: Jalid Sehouli
Session: Poster Display session 2
Resources:
Abstract
740 - A real-world analysis of the treatment of advanced ovarian cancer with PARPIs
Presenter: Alejandra Martinez de Pinillos
Session: Poster Display session 2
Resources:
Abstract
5867 - Incidence of tumour BRCA1/2 variants in relapsed, platinum-sensitive ovarian, fallopian tube and primary peritoneal cancer
Presenter: Robert Morgan
Session: Poster Display session 2
Resources:
Abstract
2966 - Frequency of mutations in 21 hereditary breast and ovarian cancer susceptibility genes among 882 high-risk individuals
Presenter: Jihong Liu
Session: Poster Display session 2
Resources:
Abstract
1687 - BRCA testing of 1,284 Brazilian patients for hereditary breast and ovarian cancer in a routine diagnostic setting
Presenter: Fernanda Milanezi
Session: Poster Display session 2
Resources:
Abstract
3162 - A multi-center integrative study on cancer predisposition genes in Chinese patients with epithelial ovarian carcinoma
Presenter: Changbin Zhu
Session: Poster Display session 2
Resources:
Abstract
5993 - Incidental Early Occult Ovarian Cancer after Risk-Reducing Salpingo-Oophorectomy in BRCA1/2 Mutation Carriers followed in a Community Public Hospital
Presenter: Begona Grana Suarez
Session: Poster Display session 2
Resources:
Abstract
5334 - Response to chemotherapy in ovarian cancer (OC) patients with or without prior breast cancer (BC), stratified by BRCA mutation (BRCAm) status
Presenter: Angela George
Session: Poster Display session 2
Resources:
Abstract
4565 - Advanced ovarian cancer: is residual disease after debulking surgery affected by genetics factors involved in angiogenesis and immunity pathways?
Presenter: Michele Bartoletti
Session: Poster Display session 2
Resources:
Abstract
3251 - Surrogate endpoint of progression-free (PFS) and overall survival (OS) for advanced ovarian cancer (AOC) patients (pts) treated with neo-adjuvant chemotherapy (NACT): Results of the CHIVA randomized phase II GINECO study
Presenter: Fabrice Lecuru
Session: Poster Display session 2
Resources:
Abstract